Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 58 citations · 29 references
Life SciencesHematologyImmunologyClinical ImmunologyImmunotherapyTransplant ImmunologyDonor Lymphocyte InfusionGraft-versus-host DiseaseHistocompatibilityTransplant PharmacologyAlemtuzumab UseAlemtuzumab-based ConditioningDonor-recipient ChimerismHematopoietic ChimerismPost-transplant ChimerismPost-transplant Relapse ProphylaxisPredictors Of Disease RecurrenceProphylactic Donor Lymphocyte Infusion
We analyzed the kinetics of CD3 chimerism in 120 consecutive allogeneic hematopoietic cell transplantation (HCT) recipients receiving alemtuzumab-based conditioning. Fifty-two received fludarabine/melphalan, 44 received fludarabine/busulfan, and 24 received clofarabine/melphalan in addition to alemtuzumab. Post-transplant GVHD prophylaxis consisted of tacrolimus. No prophylactic donor lymphocyte infusion or other interventions were used for mixed donor chimerism (MDC). Bone marrow (BM) and/or peripheral blood (PB) samples were obtained at 30 days, 100 days, 180 days, and 1 year following HCT. On Day 30, 15% of assessable patients had MDC in the CD3 compartment. This had increased to 50% by Day 100, and to 63% by Day 180. MDC predicted for a lower risk of acute (p = 0.08) and particularly of chronic GVHD (p = 0.01). MDC was not associated with subsequent relapse or TRM (p = 0.67 and 0.72, respectively). A decline of more than 15% in CD3 chimerism between Day 30 and Day 180 predicted for a 40% risk of subsequent disease recurrence. The observation of MDC after alemtuzumab conditioning does not by itself constitute a risk factor for relapse and should not be used to guide therapeutic intervention. By contrast, declining donor chimerism between Day 30 and Day 180 is associated with a somewhat increased risk of disease recurrence. The high incidence of MDC after alemtuzumab containing conditioning contributes to the low risk of acute and chronic GVHD.
29
Madan Jagasia, Hildegard Greinix, Mukta Arora et al. · Biology of Blood and Marrow Transplantation · 2014 · 5.4K citations · Full text
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Alexandra H. Filipovich, Daniel J. Weisdorf, Steven Z. Pavletic et al. · Biology of Blood and Marrow Transplantation · 2005 · 3.5K citations
The Medical Journal of Australia · 1999 · 3.4K citations